Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trialWilliam D. Tap, Andrew J. Wagner, Michiel A. J. van de Sande et al.|The Lancet|2019Cited by 472
Reporting, Appraising, and Integrating Data on Genotype Prevalence and Gene-Disease AssociationsJulian Little, Clarice R. Weinberg, Linda Bradley et al.|American Journal of Epidemiology|2002Cited by 372
Li-Fraumeni syndrome: cancer risk assessment and clinical managementKate A. McBride, Gillian Mitchell, Mandy L. Ballinger et al.|Nature Reviews Clinical Oncology|2014Cited by 276
Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With OsteosarcomaSharon A. Savage, Bin Zhu, Roelof Koster et al.|JAMA Oncology|2020Cited by 251
Monogenic and polygenic determinants of sarcoma risk: an international genetic studyMandy L. Ballinger, David M. Thomas, David L. Goode et al.|The Lancet Oncology|2016Cited by 213